Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 99 of 114

  1. Upadacitinib

    AbbVie

    Hidradenitis Suppurativa

    phase 3 small molecule active

    1 trial

  2. Upadacitinib

    AbbVie

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. Upadacitinib (ABT-494)

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  4. Upadacitinib Placebo, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    non-segmental vitiligo

    phase 3 small molecule active

    1 trial

  5. Ustekinumab

    The First People's Hospital of Lianyungang

    Crohn Disease

    phase 3 small molecule active

    1 trial

  6. Ustekinumab Dose Based on BSA and Body Weight

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  7. Usual Care

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 3 small molecule completed

    1 trial

  8. V00018PC303

    Pierre Fabre Medicament

    Cessation of smoking

    phase 3 small molecule active

    1 trial

  9. V114

    Merck KGaA, Darmstadt, Germany

    Acute Otitis Media (AOM)

    phase 3 mab completed

    1 trial

  10. V114

    Merck KGaA, Darmstadt, Germany

    Pneumococcal Infections

    phase 3 mab completed

    1 trial

  11. V116-013

    Merck Sharp and Dohme

    Pneumococcal disease

    phase 3 small molecule active

    1 trial

  12. V118_18

    Seqirus (Australia) Pty Ltd

    Influenza

    phase 3 mab completed

    1 trial

  13. V181

    Merck KGaA, Darmstadt, Germany

    Healthy

    phase 3 mab active

    1 trial

  14. V503-021

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 small molecule active

    1 trial

  15. V712-305/EPOPEX

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  16. V712-308

    DBV Technologies

    Peanut allergy

    phase 3 small molecule active

    1 trial

  17. V940-002

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. V940-007

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  19. V940-009

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. VACAB-2022

    The George Institute

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial

  21. VAD00004

    Sanofi-aventis Healthcare Pty Ltd

    Virus diseases

    phase 3 small molecule active

    1 trial

  22. VATS

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer

    phase 3 other active

    1 trial

  23. VAY736

    Novartis Pharmaceuticals

    Sjogren Syndrome

    phase 3 mab active

    1 trial

  24. VAY736F12301E1

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  25. VEC-162 20 mg

    Vanda Pharmaceuticals Netherlands B.V.

    Primary Insomnia

    phase 3 small molecule completed

    1 trial

  26. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  27. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Myopia, Pathological

    phase 3 mab completed

    1 trial

  28. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Diabetes Mellitus

    phase 3 mab completed

    1 trial

  29. VEGF Trap-Eye 2.0mg

    Regeneron UK Limited

    Macular Edema Secondary to Central Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  30. VERDYE 5 mg/ml poeder voor oplossing voor injectie

    Disc Medicine

    Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)

    phase 3 small molecule active

    1 trial

  31. VERIFY

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  32. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Cervical Dysplasia

    phase 3 mab completed

    2 trials

  33. VIB0551.P3.S1

    Elan Pharma International

    Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).

    phase 3 small molecule active

    1 trial

  34. VIB0551.P3.S2

    Elan Pharma International

    Immunoglobulin G4-related disease (IgG4-RD)

    phase 3 small molecule active

    1 trial

  35. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  36. VIR-7831

    Vir Biotechnology

    COVID-19

    phase 3 mab completed

    1 trial

  37. VIR-7831 (sotrovimab)

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  38. VIR-CHDV-V205

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  39. VISIPAQUE d’I/mL for Knee OsteoArthritis

    Pari Pharma GmbH

    Knee OsteoArthritis

    phase 3 small molecule active

    1 trial

  40. VK2735

    Viking Therapeutics

    Weight Loss

    phase 3 small molecule active

    4 trials

  41. VNZ/TEZ/D-IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    4 trials

  42. VONVENDI

    Takeda

    Von Willebrand Disease (VWD)

    phase 3 mab active

    1 trial

  43. VP-102

    Verrica Pharmaceuticals

    Common Warts

    phase 3 other active

    1 trial

  44. VP-102-101

    Verrica Pharmaceuticals

    Molluscum Contagiosum

    phase 3 other completed

    2 trials

  45. VP-VEC-162-3108

    Lacuna Pharma Pty Ltd

    Insomnia Disorder

    phase 3 small molecule active

    1 trial

  46. VP-VEC-162-3502

    Lacuna Pharma Pty Ltd

    Delayed Sleep-Wake Phase Disorder (DSWPD)

    phase 3 small molecule active

    1 trial

  47. VP-VEC-162-3601

    Vanda Pharmaceuticals Netherlands B.V.

    Autism Spectrum Disorder

    phase 3 small molecule active

    1 trial

  48. VP-VHX-896-3201

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.